Key result
Semaglutide is linked to ~34% lower mortality vs DPP-4 inhibitors in adult congenital heart disease.
Why the study?
Does semaglutide reduce all-cause mortality and cardiovascular events compared to DPP-4 inhibitors in adults with congenital heart disease and type 2 diabetes mellitus?
Cohort (n=5,274)
Yes
Does semaglutide reduce all-cause mortality and cardiovascular events compared to DPP-4 inhibitors in adults with congenital heart disease and type 2 diabetes mellitus?
In a large propensity-matched cohort of adults with predominantly simple-to-moderate congenital heart disease and type 2 diabetes, semaglutide was associated with lower mortality and acute care utilization than DPP-4 inhibitors, though residual confounding by healthcare engagement likely contributed.
Answers are grounded in this paper and cite their sources.
May support semaglutide preference in this population; leaves open causality amid residual confounding by healthcare engagement.
Adults with congenital heart disease (ACHD) increasingly develop type 2 diabetes mellitus (T2DM) and obesity, yet are excluded from cardiovascular outcome trials, and the effects of semaglutide here are unknown. Using the TriNetX Research Network, we conducted a retrospective new-user active-comparator study of adults with ACHD and T2DM initiating semaglutide (n = 2,385) or a dipeptidyl peptidase-4 (DPP-4) inhibitor (n = 2,889) from December 2017 to December 2025. Cohorts were 1:1 propensity score matched, yielding 1,422 pairs followed for 3 years, with a sensitivity analysis matched on 27 lesion categories. Semaglutide was associated with lower all-cause mortality (7% vs 12%; hazard ratio [HR] 0.66, 95% confidence interval [CI] 0.51 to 0.85), hospitalization (40% vs 55%; HR 0.68, CI 0.61 to 0.76), and emergency department (ED) visits (35% vs 43%; HR 0.85, CI 0.75 to 0.96). Major adverse cardiovascular events (HR 0.71), heart failure (HR 0.74), and stroke (HR 0.65) were also lower; myocardial infarction and arrhythmia were not. Mortality, hospitalization, and ED visits were significant at 1, 3, and 5 years and in every sensitivity analysis; the cardiovascular associations were not. Congenital aortic valve disease was twice as common among semaglutide initiators before matching (23% vs 12%), and every great-complexity lesion comprised ≤10 patients per arm. A prespecified negative control was elevated in every analysis. In conclusion, semaglutide was associated with lower mortality and acute care utilization in a predominantly simple-to-moderate complexity ACHD population, but an elevated negative control indicates residual differences in healthcare engagement; these findings are hypothesis-generating.
No takes yet. Share an insight, caveat, or question.
Chough et al. (2026) conducted a cohort in Adults with congenital heart disease (ACHD) and type 2 diabetes mellitus (T2DM) (n=5,274). Semaglutide vs. Dipeptidyl peptidase-4 (DPP-4) inhibitor was evaluated on All-cause mortality (HR 0.66, 95% CI 0.51-0.85). Semaglutide was associated with lower all-cause mortality compared to DPP-4 inhibitors in adults with congenital heart disease and T2DM.
Synapse has enriched 10 related papers. Consider them for comparative context: